"Many newly diagnosed prostate cancers present as low Gleason score tumors that require no treatment intervention.
Distinguishing the many indolent tumors from the minority of lethal ones remains a major clinical challenge.
We now show that low Gleason score prostate tumors can be distinguished as indolent and aggressive subgroups
on the basis of their expression of genes associated with aging and senescence...
We then further classified this signature with a decision tree learning model to identify three genes—FGFR1, PMP22, and CDKN1A—
that together accurately predicted outcome of low Gleason score tumors...
Furthermore, protein expression of this three-gene panel in biopsy samples distinguished Gleason 6 patients
who failed surveillance over a 10-year period. We propose that this signature may be incorporated into prognostic assays
for monitoring patients on active surveillance to facilitate appropriate courses of treatment"
http://m.stm.sciencemag.org/content/5/202/202ra122
Our view:
Invest some money 20 years earlier in basic research / cancer research.
Do not spend a lot of money 20 years too late.